These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

266 related items for PubMed ID: 25714044

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Persistence of Immunity When Using Different Human Papillomavirus Vaccination Schedules and Booster-Dose Effects 5 Years After Primary Vaccination.
    Lazcano-Ponce E, Torres-Ibarra L, Cruz-Valdez A, Salmerón J, Barrientos-Gutiérrez T, Prado-Galbarro J, Stanley M, Muñoz N, Herrero R, Hernández-Ávila M.
    J Infect Dis; 2019 Jan 01; 219(1):41-49. PubMed ID: 30085139
    [Abstract] [Full Text] [Related]

  • 3. Immunogenicity of quadrivalent HPV and combined hepatitis A and B vaccine when co-administered or administered one month apart to 9-10 year-old girls according to 0-6 month schedule.
    Gilca V, Sauvageau C, Boulianne N, De Serres G, Couillard M, Krajden M, Ouakki M, Murphy D, Trevisan A, Dionne M.
    Hum Vaccin Immunother; 2014 Jan 01; 10(8):2438-45. PubMed ID: 25424952
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Long intervals between two doses of HPV vaccines and magnitude of the immune response: a post hoc analysis of two clinical trials.
    Gilca V, Sauvageau C, Panicker G, De Serres G, Schiller J, Ouakki M, Unger ER.
    Hum Vaccin Immunother; 2019 Jan 01; 15(7-8):1980-1985. PubMed ID: 31017850
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa.
    Mugo N, Ansah NA, Marino D, Saah A, Garner EI.
    Hum Vaccin Immunother; 2015 Jan 01; 11(6):1323-30. PubMed ID: 25912475
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Antibody persistence after a single dose of quadrivalent HPV vaccine and the effect of a dose of nonavalent vaccine given 3-8 years later - an exploratory study.
    Gilca V, Sauvageau C, Panicker G, De Serres G, Ouakki M, Unger ER.
    Hum Vaccin Immunother; 2019 Jan 01; 15(2):503-507. PubMed ID: 30252583
    [Abstract] [Full Text] [Related]

  • 13. A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9-15-Year-Old Girls.
    Vesikari T, Brodszki N, van Damme P, Diez-Domingo J, Icardi G, Petersen LK, Tran C, Thomas S, Luxembourg A, Baudin M.
    Pediatr Infect Dis J; 2015 Sep 01; 34(9):992-8. PubMed ID: 26090572
    [Abstract] [Full Text] [Related]

  • 14. Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine - A randomized clinical trial.
    Gilca V, Sauvageau C, Panicker G, De Serres G, Ouakki M, Unger ER.
    Vaccine; 2018 Nov 12; 36(46):7017-7024. PubMed ID: 30314913
    [Abstract] [Full Text] [Related]

  • 15. Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes.
    Barzon L, Squarzon L, Masiero S, Pacenti M, Marcati G, Mantelli B, Gabrielli L, Pascucci MG, Lazzarotto T, Caputo A, Palù G.
    Vaccine; 2014 Sep 15; 32(41):5357-62. PubMed ID: 25045814
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials.
    Mariz FC, Gray P, Bender N, Eriksson T, Kann H, Apter D, Paavonen J, Pajunen E, Prager KM, Sehr P, Surcel HM, Waterboer T, Müller M, Pawlita M, Lehtinen M.
    Lancet Infect Dis; 2021 Oct 15; 21(10):1458-1468. PubMed ID: 34081923
    [Abstract] [Full Text] [Related]

  • 19. The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassay.
    Brown DR, Garland SM, Ferris DG, Joura E, Steben M, James M, Radley D, Vuocolo S, Garner EI, Haupt RM, Bryan JT.
    Hum Vaccin; 2011 Feb 15; 7(2):230-8. PubMed ID: 21307649
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.